A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

This study tests whether adding a drug called siltuximab to a standard high-dose chemotherapy drug (melphalan) before a stem cell transplant improves outcomes for people with multiple myeloma (a cancer of blood plasma cells). **You may be eligible if...** - You are at least 60 years old - You have been diagnosed with multiple myeloma and are planning to have an autologous stem cell transplant (using your own stem cells) within 12 months of diagnosis - Your heart, lungs, liver, and kidneys are functioning at an adequate level - You have enough stored stem cells to proceed with transplant **You may NOT be eligible if...** - You have previously received treatments that target the IL-6 protein - You have had another cancer in the past 2 years (some exceptions apply) - You have uncontrolled heart failure, a recent heart procedure, or a significant irregular heartbeat - You have HIV, active hepatitis B or C infections - You have participated in another experimental drug study within the past two weeks Talk to your doctor to see if this trial is right for you.